MedKoo Cat#: 526941 | Name: SCH-37370

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SCH-37370 is a potent, orally active, dual antagonist of platelet-activating factor and histamine. Sch 37370 selectively inhibits PAF-induced aggregation of human platelets (IC50 = 0.6 microM) and also competes with PAF binding to specific sites in membrane preparations from human lungs (IC50 = 1.2 microM). Sch 37370 blocks the binding of [3H]pyrilamine to histamine-H1 receptors in rat brain membranes.

Chemical Structure

SCH-37370
SCH-37370
CAS#117796-52-8

Theoretical Analysis

MedKoo Cat#: 526941

Name: SCH-37370

CAS#: 117796-52-8

Chemical Formula: C21H21ClN2O

Exact Mass: 352.1342

Molecular Weight: 352.86

Elemental Analysis: C, 71.48; H, 6.00; Cl, 10.05; N, 7.94; O, 4.53

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SCH-37370; SCH 37370; SCH37370.
IUPAC/Chemical Name
1-(4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidin-1-yl)ethan-1-one
InChi Key
InChi Code
SMILES Code
ClC1=CC=C2C(CCC3=CC=CN=C3/C2=C4CCN(C(C)=O)CC/4)=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 352.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kaminski JJ, Carruthers NI, Wong SC, Chan TM, Billah MM, Tozzi S, McPhail AT. Conformational considerations in the design of dual antagonists of platelet-activating factor (PAF) and histamine. Bioorg Med Chem. 1999 Jul;7(7):1413-23. PubMed PMID: 10465415. 2: Centemeri C, Colli S, Tosarello D, Ciceri P, Nicosia S. Heterogeneous platelet-activating factor (PAF) receptors and calcium increase in platelets and macrophages. Biochem Pharmacol. 1999 Feb 1;57(3):263-71. PubMed PMID: 9890553. 3: Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010. 4: Balsa D, Merlos M, Giral M, Ferrando R, García-Rafanell J, Forn J. Characterization of [3H]apafant binding to PAF receptor on rabbit platelet membranes: a comparison of a microplate filtration system and a standard method. J Pharmacol Toxicol Methods. 1996 Sep;36(1):53-62. PubMed PMID: 8872920. 5: Billah MM, Gilchrest HG, Eckel SP, Granzow CA, Lawton PJ, Radwanski E, Brannan MD, Affrime MB, Christopher JD, Richards W, et al. Differential plasma duration of antiplatelet-activating factor and antihistamine activities of oral Sch 37370 in humans. Clin Pharmacol Ther. 1992 Aug;52(2):151-9. PubMed PMID: 1505150. 6: Billah MM, Egan RW, Ganguly AK, Green MJ, Kreutner W, Piwinski JJ, Siegel MI, Villani FJ, Wong JK. Discovery and preliminary pharmacology of Sch 37370, a dual antagonist of PAF and histamine. Lipids. 1991 Dec;26(12):1172-4. PubMed PMID: 1819703. 7: Billah MM, Chapman RW, Watnick AS, Egan RW, Siegel MI, Kreutner W. Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21. PubMed PMID: 1793070. 8: Billah MM, Chapman RW, Egan RW, Gilchrest H, Piwinski JJ, Sherwood J, Siegel MI, West RE Jr, Kreutner W. Sch 37370: a potent, orally active, dual antagonist of platelet-activating factor and histamine. J Pharmacol Exp Ther. 1990 Mar;252(3):1090-6. PubMed PMID: 2319461.